i-Seq Biotechnology, Inc. utilizes CRISPR interference screening (CRISPRi-Seq) to identify new vaccine antigens and therapeutic targets for infectious diseases. The company addresses the limitations of existing narrow-spectrum vaccines and the challenges posed by antibiotic resistance in treating infections.
Funding
Funding not disclosed
Founders
Product
Problem
Current vaccines often have a narrow spectrum of protection, and the increasing prevalence of antibiotic resistance poses significant challenges in treating infectious diseases. These limitations hinder effective prevention and treatment strategies for a wide range of infections.
Solution
i-Seq Biotechnology leverages CRISPR interference screening (CRISPRi-Seq) to identify novel, broad-spectrum vaccine antigens and therapeutic targets for infectious diseases. Their technology assesses genome-wide gene fitness in a single step, enabling the discovery of targets that can overcome the limitations of existing narrow-spectrum vaccines and address the challenges posed by antibiotic resistance. This approach aims to develop innovative vaccines and therapeutics that offer broader protection and more effective treatment options against a variety of infectious pathogens.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing new vaccines and therapeutics for infectious diseases.
Features
- CRISPR interference screening (CRISPRi-Seq) technology for genome-wide gene fitness assessment.
- Identification of novel vaccine antigens and therapeutic targets.
- Focus on developing broad-spectrum vaccines.
- Aims to address the challenge of antibiotic resistance.